Pegylated IFN alpha-2b/Ribavirin therapy for chronic hepatitis C with genotype Ib, high titer-analysis with viral clearance.

Pegylated IFN alpha-2b/Ribavirin therapy for chronic hepatitis C with genotype Ib, high titer-analysis with viral clearance. - GLSG PEG/Rib 2005

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000175

Enrollment

250

Registered

2005-09-12

Start date

2005-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

Negative for HCVRNA at 4 weeks of therapy. PEG-IFN alpha-2b/ribavirin (48weeks) Positive for HCVRNA at 4 weeks of therapy. PEG-IFN alpha-2b/ribavirin (48 weeks) Positive for HCVRNA at 4 weeks of t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Chronic hepatitis C with genotype Ia/Ib and high titer (more than 100KIU/ml) (2)Chronic hepatitis confirmed with liver biopsy. (3)Abnormal ALT

Exclusion criteria

Exclusion criteria: (1)Complicated with other liver diseases such as autoimmune hepatitis and alcoholic liver injury. (2)Liver cirrhosis, hepatic failure. (3)Drug allergy for IFN or ribavirin. (4)Drug allergy for vaccine. (5)Administration of other anti-viral or immunomodulatory treatment. (6)Pregnancy. (7)Depression. (8)Complicated with autoimmune disorders.

Design outcomes

Primary

Measure	Time frame
Sustained virological response rate	—

Countries

Japan

Contacts

Public ContactSatoru Kakizaki

Gunma University Graduate School of Medicine Department of Medicine and Molecular Science

kakizaki@showa.gunma-u.ac.jp027-220-8127

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026